Aquila Capital
Aquila Capital is a private investment firm based in Hamburg, Germany, founded in 2001. It specializes in providing institutional investors, pension funds, foundations, and individuals with alternative investment solutions across real assets, financial markets, and private equity. The firm employs a multi-disciplinary investment approach, leveraging a team of dedicated specialists to manage a diverse range of investments, including hedge funds, private equity fund of funds, real estate, and infrastructure projects. Aquila Capital emphasizes strong operational frameworks and corporate governance to enhance its investment management capabilities. The firm operates additional offices in Frankfurt, Munich, and Vienna, and aims to identify and manage attractive investment opportunities for its clients through a solution-oriented approach that encompasses strategy development, implementation, and asset management.
Top Stages
2 past transactions
Energias de Portugal
Acquisition in 2018
Energias de Portugal (EDP) is a prominent global energy company based in Lisbon, Portugal, founded in 1976. It operates primarily in the electricity and gas sectors, offering services in generation, distribution, and trading. EDP is one of the largest energy operators in the Iberian Peninsula and ranks as the third-largest producer of wind energy in the region. The company emphasizes value creation, innovation, and sustainability, reflecting its commitment to customers, society, and the environment. EDP's diverse workforce spans multiple continents, fostering a culture that respects the various markets in which it operates. Additionally, EDP is recognized for its performance in transparency and sustainability, as evidenced by its inclusion in the Dow Jones Sustainability Indexes.
Argenx
Post in 2016
Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.